{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Study treatment will be held/interrupted if:', 'Results from the repeat laboratory testing are not available at the time of the next', 'scheduled dose', 'ALT and/or AST remains >3x ULN with total bilirubin <2x ULN after repeat', 'laboratory testing.', 'Subjects have an active or clinically significant infection.', 'Subject has a suspected malignancy (with the exception of local and resected basal or', 'squamous cell carcinoma of the skin), after confirmation with the Medical Monitor.', 'Temporary interruption of study treatment should also be considered if, at the discretion of', 'the Investigator, it is necessary for safety reasons (e.g., negative trends during laboratory', 'monitoring or remaining abnormalities after retesting which do not require premature', 'discontinuation of the study treatment but could be harmful for the patient according to the', \"Investigator's judgement [Section 7.4.6.2], or other clinically significant newly diagnosed\", 'co-morbidity that requires additional assessments for clarification of the diagnosis, and the', 'severity of which could worsen if study treatment is continued).', '6.11.2', 'Permanent Discontinuation of Study Treatment', 'The criteria for enrollment are to be followed explicitly.', 'If a subject who does not meet enrollment criteria is inadvertently enrolled, R-Pharm', \"International or R-Pharm International's designee must be informed immediately, and the\", 'subject may be discontinued from study treatment.', 'If, in the opinion of the Investigator, a subject is consistently noncompliant with the protocol', 'in regards to study procedures, use of concomitant medications, or dosing with the study', \"treatment, R-Pharm International or R-Pharm International's designee must be informed as\", 'soon as it can be possible, and the case will be reviewed by R-Pharm International on a', 'case-by-case basis and the noncompliant subject can be discontinued from the study', 'treatment.', \"If the Investigator judges that the subject's health is deteriorating or not improving, the\", 'Investigator can elect to discontinue the subject from the study treatment. Appropriate', 'standard of care, at the discretion of the Investigator, will be initiated.', 'In addition to the above, study treatment will be discontinued in the following circumstances:', 'Investigator decides that the subject should be discontinued from the study treatment.', 'If this decision is made because of an intolerable AE or a clinically significant', 'Amendment 2: 06 March 2019', '82', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'laboratory value, the study treatment is to be discontinued, appropriate measures are to', \"be taken, and R-Pharm International or R-Pharm International's designee is to be\", 'notified.', 'Subject is unwilling to continue the study treatment. If the subject discontinues from', 'the study treatment, the Investigator should inquire about the reason for discontinuing.', 'Subject presents with any of the following elevated LFTs (see also Appendix 1', '[Section 13.1]):', '-', 'ALT or AST elevations >8x ULN at any time, regardless of total bilirubin or', 'accompanying symptoms', '-', 'ALT or AST >5x ULN for >2 weeks regardless of total bilirubin or accompanying', 'symptoms. The elevation should be continuous for >2 consecutive weeks. If the', 'level decreases for some time within 2 weeks, subject permanent discontinuation is', 'not mandated, but left under Investigator discretion. Resuming the IMP should be', 'discussed on a case by case basis.', '- ALT or AST elevations >3x ULN and total bilirubin value >2x ULN at any time', '- AST or ALT elevations >3x ULN accompanied by symptoms which, as determined', 'by the Investigator, are the result of hepatic injury (e.g., fatigue, nausea, vomiting,', 'right upper quadrant pain or tenderness, fever, rash, eosinophilia [>5%])', 'Subject presents with any of the following laboratory abnormalities:', '- Absolute neutrophil count <500x106/L (<500/mm\u00b3)', '- Two sequential lymphocyte counts <500x106/L (<500/mm\u00b3)', '- Platelet count <50x10%/L (<50,000/mm\u00b3 or <50,000x106/L)', '- Two sequential hemoglobin values 8.0 g/dL and decreased >20 g/L (2 g/dL) below', 'OLE Baseline', '- Creatinine value >2x ULN', 'Subject has confirmation of a pregnancy during the study, as evidenced by a positive', 'pregnancy test.', 'R-Pharm International, a regulatory agency, or an ethical committee stops the study', 'for any reason.', 'Subject has a GI perforation.', 'Amendment 2: 06 March 2019', '83', 'Confidential']\n\n###\n\n", "completion": "END"}